Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno-and Undifferentiated Carcinoma of Unknown Primary

Background: Carcinomas of unknown primary (CUP) account for approximately 2–5% of all cancer diagnoses. Except for some subsets with favorable prognosis, for most of these patients